Unity Biotechnology Stock Buy Hold or Sell Recommendation
| UBX Stock | USD 1.15 0.05 4.17% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Unity Biotechnology is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Unity Biotechnology given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Unity Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Unity Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide. In addition, we conduct extensive research on individual companies such as Unity and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Unity Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Unity |
Execute Unity Biotechnology Buy or Sell Advice
The Unity recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Unity Biotechnology. Macroaxis does not own or have any residual interests in Unity Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Unity Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Unity Biotechnology Trading Alerts and Improvement Suggestions
| Unity Biotechnology is way too risky over 90 days horizon | |
| Unity Biotechnology may become a speculative penny stock | |
| Unity Biotechnology appears to be risky and price may revert if volatility continues | |
| Unity Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Reported Net Loss for the year was (25.99 M) with loss before taxes, overhead, and interest of (13.01 M). | |
| Unity Biotechnology has about 64.51 M in cash with (20.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Unity Biotechnology has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: UBX Stock Down 29 percent on Mixed Results From Phase II Eye Disease Study |
Unity Biotechnology Returns Distribution Density
The distribution of Unity Biotechnology's historical returns is an attempt to chart the uncertainty of Unity Biotechnology's future price movements. The chart of the probability distribution of Unity Biotechnology daily returns describes the distribution of returns around its average expected value. We use Unity Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Unity Biotechnology returns is essential to provide solid investment advice for Unity Biotechnology.
| Mean Return | 0.76 |
| Value At Risk | -9.36 |
| Potential Upside | 16.76 |
| Standard Deviation | 10.13 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Unity Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Unity Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Unity Biotechnology, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Unity Biotechnology back and forth among themselves.
| Shares | |||
| State Street Corp | 2024-12-31 | 37.8 K | |
| Commonwealth Equity Services Inc | 2024-12-31 | 24.2 K | |
| Northern Trust Corp | 2024-12-31 | 22.5 K | |
| Jane Street Group Llc | 2024-12-31 | 21.2 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 18.7 K | |
| Squarepoint Ops Llc | 2024-12-31 | 18.3 K | |
| Endowment Wealth Management, Inc. | 2024-12-31 | 12.5 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 11.3 K | |
| Ubs Group Ag | 2024-12-31 | 8.2 K | |
| Arch Venture Corp | 2024-12-31 | 1 M | |
| Alyeska Investment Group, L.p. | 2024-12-31 | 859.1 K |
Unity Biotechnology Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (5.2M) | 39.5M | (24.8M) | 60.5M | 8.6M | 9.0M | |
| Change In Cash | (19.7M) | 15.1M | (20.7M) | 7.1M | (12.2M) | (11.6M) | |
| Net Borrowings | 821K | (73K) | 24.5M | (68K) | (61.2K) | (58.1K) | |
| Free Cash Flow | (79.0M) | (45.3M) | (51.1M) | (37.1M) | (20.9M) | (21.9M) | |
| Depreciation | 2.7M | 3.4M | 2.9M | 1.2M | 867K | 823.7K | |
| Other Non Cash Items | 420K | 943K | (1.6M) | (3.0M) | (3.1M) | (2.9M) | |
| Capital Expenditures | 1.6M | 646K | 195K | 96K | 11K | 0.0 | |
| Net Income | (93.8M) | (60.7M) | (59.9M) | (39.9M) | (26.0M) | (27.3M) | |
| End Period Cash Flow | 19.3M | 34.4M | 13.6M | 20.7M | 8.5M | 8.1M | |
| Change To Netincome | 10.9M | 16.3M | 12.6M | 8.8M | 10.2M | 11.6M |
Unity Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Unity Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Unity Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Unity stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.75 | |
β | Beta against Dow Jones | -1.33 | |
σ | Overall volatility | 10.59 | |
Ir | Information ratio | 0.07 |
Unity Biotechnology Volatility Alert
Unity Biotechnology is displaying above-average volatility over the selected time horizon. Unity Biotechnology is a potential penny stock. Although Unity Biotechnology may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Unity Biotechnology. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Unity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Unity Biotechnology Fundamentals Vs Peers
Comparing Unity Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Unity Biotechnology's direct or indirect competition across all of the common fundamentals between Unity Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Unity Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Unity Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Unity Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Unity Biotechnology to competition |
| Fundamentals | Unity Biotechnology | Peer Average |
| Return On Equity | -1.49 | -0.31 |
| Return On Asset | -0.34 | -0.14 |
| Current Valuation | 21.65 M | 16.62 B |
| Shares Outstanding | 16.87 M | 571.82 M |
| Shares Owned By Insiders | 1.30 % | 10.09 % |
| Shares Owned By Institutions | 19.58 % | 39.21 % |
| Number Of Shares Shorted | 516.33 K | 4.71 M |
| Price To Book | 3.29 X | 9.51 X |
| Price To Sales | 6.54 X | 11.42 X |
| Gross Profit | (13.01 M) | 27.38 B |
| EBITDA | (31.17 M) | 3.9 B |
| Net Income | (25.99 M) | 570.98 M |
| Cash And Equivalents | 64.51 M | 2.7 B |
| Cash Per Share | 9.26 X | 5.01 X |
| Total Debt | 19.71 M | 5.32 B |
| Debt To Equity | 1.30 % | 48.70 % |
| Current Ratio | 4.13 X | 2.16 X |
| Book Value Per Share | 0.39 X | 1.93 K |
| Cash Flow From Operations | (20.86 M) | 971.22 M |
| Short Ratio | 5.24 X | 4.00 X |
| Earnings Per Share | (1.46) X | 3.12 X |
| Target Price | 5.0 | |
| Number Of Employees | 16 | 18.84 K |
| Beta | 1.02 | -0.15 |
| Market Capitalization | 21.34 M | 19.03 B |
| Total Asset | 37.66 M | 29.47 B |
| Retained Earnings | (510.34 M) | 9.33 B |
| Working Capital | 15.01 M | 1.48 B |
| Net Asset | 37.66 M |
Note: Acquisition by Nguyen Alexander Hieu of 150000 shares of Unity Biotechnology at 2.09 subject to Rule 16b-3 [view details]
Unity Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Unity . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 1.15 | |||
| Day Typical Price | 1.15 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.05) | |||
| Relative Strength Index | 50.63 |
About Unity Biotechnology Buy or Sell Advice
When is the right time to buy or sell Unity Biotechnology? Buying financial instruments such as Unity Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Unity Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Trading Thematic Idea Now
Trading
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Trading theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trading Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.